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A B S T R A C T
A new member of the chicken TNF superfamily has recently been identiﬁed, namely receptor activator
of NF-κB ligand (RANKL), as have its signalling receptor, RANK, and its decoy receptor, osteoprotegerin
(OPG). In mammals, RANKL and RANK are transmembrane proteins expressed on the surface of Th1 cells
and dendritic cells (DC) respectively, whereas OPG is expressed as a soluble protein from osteoblasts and
DC. Recombinant soluble chicken RANKL (chRANKL) forms homotrimers whereas chicken OPG (chOPG)
forms homodimers, characteristic of these molecules in mammals. ChRANKL, chRANK and chOPG are
expressed at the mRNA level in most tissues and organs. ChRANKL is transcriptionally regulated by Ca2+
mobilisation and enhances the mRNA expression levels of pro-inﬂammatory cytokines in bone marrow-
derived DC (BMDC); this is inhibited by both chOPG-Fc and soluble chRANK-Fc. However, chRANKL does
not enhance the expression of cell surface markers in either BMDC or BM-derived macrophages (BMM).
Furthermore, chRANKL enhances the survival of APC similar to its mammalian orthologue.
© 2015 Published by Elsevier Ltd.
1. Introduction
Members of the TNF superfamily are key regulators of the activ-
ity of a variety of pathways associated with the regulation and
modulation of the immune system. The TNF superfamily is made up
of TNF ligands and their respective receptor(s). The signals from the
receptor members of the TNF (TNFR) superfamily control survival
versus death signals but also have a role in regulatory events, such
as controlling cytokine and chemokine expression (Locksley et al.,
2001). Members of the TNFR superfamily are characteristically type
I transmembrane proteins that have low degrees of homology and
are grouped due to the presence of conserved cysteine-rich domains
(CRD) in their extracellular ligand-binding domains (Naismith and
Sprang, 1998). The CRD are typically deﬁned by three intra-chain
disulphide bridges generated between highly conserved cysteine resi-
dues that act as a scaffold to produce an elongated structure protruding
from the cell (Smith et al., 1994). The TNFR superfamily can be further
categorised by the expression of either TNFR-associated factors (TRAF)-
binding motifs or death domains (DD). The DD receptors are
characterised by the presence of an ~80 amino acids (aa) cytoplas-
mic sequence necessary for apoptosis (Nagata, 1997). TNF superfamily
ligands are mostly type II transmembrane proteins with an extra-
cellular site for proteolytic cleavage to release a soluble protein from
the membrane. All TNF superfamily ligands share a common struc-
tural core, a scaffold of ten hydrogen bonds that assumes a jelly-roll
β-sandwich fold (Lam et al., 2001).
Analysis of the chicken genome has identiﬁed a reduced reper-
toire for the TNF superfamily compared to those of mammals (Kaiser
et al., 2005). Other cytokine families, including the type I and type
III IFN, IL-1, IL-10, IL-12 and chemokine families (Kaiser, 2010, 2012)
also have a reduced repertoire compared to their mammalian equiva-
lents. For the TNF superfamily, 19 ligands and 29 receptors have been
identiﬁed in mammals, but only 10 ligands and 15 receptors in the
chicken genome. When both a ligand and its respective receptor are
not present in the chicken genome, we hypothesise that these
members are really not present rather than not annotated (Kaiser,
2012). In mammals and chickens, the TNF superfamily members are
mainly found in small sub-families of syntenic genes on different
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chromosomes. Chickens lack certain of these sub-families in their
genome and this has implications for their biology. For example, the
lack of an equivalent of the canonical mammalian lymph node in
chickens may be linked to the absence of the sub-family of genes
encoding the lymphotoxins (LT-α and LT-β) and TNF-α in their
genome. LT-α−/− mice have defects in lymph node development and
splenic architecture (Banks et al., 1995). TNF-α−/− mice develop nor-
mally but are highly susceptible to infectious agents (Pasparakis et al.,
1996). However, two receptors for TNF-α – a partial clone of TNFR1
(Bridgham and Johnson, 2001) and TNFR2 (Abdalla et al., 2004b) –
have been identiﬁed in the chicken genome. Of the ten TNF ligands
identiﬁed in the chicken genome, the biological activities of ﬁve have
so far been characterised – CD30 and TNF-related apoptosis induc-
ing ligand (TRAIL) (Abdalla et al., 2004a), B cell activating factor
(BAFF) (Schneider et al., 2004), CD40L (Tregaskes et al., 2005) and
vascular endothelial growth inhibitor (VEGI) (Takimoto et al., 2005).
Overall, the functions of these chicken TNF family members are evo-
lutionarily conserved.
Mammalian receptor activator of NF-κB ligand (RANKL), a ligand
member of the TNF superfamily, is a transmembrane protein of 316
aa containing a COOH-terminal receptor-binding domain, a 20 aa hy-
drophobic transmembrane domain and a relatively long extracellular
domain that contains a TNF-homologous domain that is the active
receptor-binding site (Anderson et al., 1997; Lam et al., 2001). Its ex-
pression in the immune system is limited to the thymus and lymph
nodes (Anderson et al., 1997;Wong et al., 1997b) a restricted pattern
of expression not usually seen for TNF superfamily members. RANKL
has two receptors, a signalling receptor, RANK, and a decoy recep-
tor, osteoprotegerin (OPG), a secreted TNF-related protein that inhibits
the RANKL–RANK interaction (Simonet et al., 1997). RANK is a type
I transmembrane protein of 616 aa, with the longest extracellular
domain (residues 234–616) of all TNFR members identiﬁed so far,
containing four CRD (Anderson et al., 1997). It is the only known sig-
nalling receptor for RANKL (Anderson et al., 1997;Wong et al., 1997b).
Originally identiﬁed in a bone marrow-derived myeloid DC cDNA
library, RANKmRNA expression iswidely detected in the lungs, spleen,
skeletal muscle, brain, liver, kidney and surface expression is de-
tected in cells of themyelomonocytic lineage ranging from osteoclast
progenitor cells to DC (Anderson et al., 1997; Wong et al., 1997b).
OPG was identiﬁed through sequence homology with the TNF su-
perfamily (Simonet et al., 1997). It contains two C-terminal
homologous DD of TNFR1 that are not functional. OPG is a natural-
ly secreted protein which can form disulphide-linked dimers of
110 kDa. Transgenic mice overexpressing OPG suffered from osteo-
petrosis and osteoclastogenesis could be inhibited by the addition
of OPG to cell cultures (Simonet et al., 1997). RANKL−/− and RANK−/−
deﬁcient mice had entirely unexpected phenotypes: early defects in
T and B cell development, complete absences of lymph nodes, se-
verely reduced osteoclastogenesis and failure to develop mammary
glands (Dougall et al., 1999; Kong et al., 1999). RANKL, RANK and OPG
have been implicated in a number of biological processes, such as
bonemetabolism (Kong et al., 1999; Simonet et al., 1997; Yasuda et al.,
1998), lymph node development (Kim et al., 2004), thymocyte de-
velopment (Hikosaka et al., 2008; Rossi et al., 2007), M cell
differentiation and maintenance (Knoop et al., 2009) and immunity
(Anderson et al., 1997).
Although RANKL−/− or RANK−/− mice expressed normal DC and
macrophages numbers and functions (Darnay et al., 1998; Kong et al.,
1999) they were deﬁcient in production of the cytokines that drive
pro-inﬂammatory immune responses. RANKL induces pro-
inﬂammatory cytokine expression in monocyte-derived and BM-
DC, driving predominantly expression of Th1 effector cytokines
(Anderson et al., 1997; Josien et al., 1999; Schiano de Colella et al.,
2008; Wong et al., 1997b). Strong RANKL surface expression is pre-
dominantly on activated murine Th1 cell clones rather than Th2 cell
clones (Josien et al., 1999). RANKL−/− T cells produce higher levels
of IL-4 and IL-5 compared to wild-type cells (Kong et al., 1999). These
studies strongly suggested that RANKL is a predominant Th1 surface
marker. RANKL transcription is upregulated within 2 h of TCR stim-
ulation. Its expression on T cells is regulated by calcium ion (Ca2+)
mobilisation and is enhanced by protein kinase C (PKC) activation
(Bishop et al., 2011; Fionda et al., 2007; Wang et al., 2002).
Various members of the TNF superfamily can upregulate the ex-
pression of costimulatory molecules on the surface of target cells.
Mammalian RANKL did not signiﬁcantly increase the surface ex-
pression of MHC class II, CD80 and CD86 on DC but did upregulate
CD40 expression (Anderson et al., 1997; Wong et al., 1997b). RANKL
induced partial maturation of monocyte-derived DC and en-
hanced the levels of CD83 and CD86 expression (Schiano de Colella
et al., 2008). Macrophages upregulate MHC class II and CD86 when
stimulated with RANKL and can further increase surface expres-
sion by synergisingwith LPS and IFN-γ (Park et al., 2005). Mammalian
RANKL is a survival factor for antigen presenting cells (APC), en-
couraging cell survival through the upregulation of the anti-
apoptotic molecule, Bcl-XL (Wong et al., 1997a).
Here we describe the cloning and molecular characterisation of
chicken RANKL (chRANKL) and its receptors, chRANK and chOPG.
The main objective of this study was to characterise the role of
chRANKL in the function of avian APC, by analysing its ability to
enhance pro-inﬂammatory cytokine mRNA expression levels, alter
APC phenotype and enhance cell survival.
2. Materials and methods
2.1. Identiﬁcation and molecular cloning of chRANKL, chRANK
and chOPG
The full-length cDNA of chRANKL and chRANKwere cloned using
primers designed to the predicted sequences of the genes in the
Ensembl and NCBI databases (see Table 1). ChOPG has previously
Table 1
Primers and probes.
Name Target Sequence (5′–3′)
RANKL Full length F: ATGCGGCGCGCCAGCCG
R:TCAGTCTAAATCCCTTACTTTAAATGCCCCA
RANK Full length F: TTGTCACTACAAAGCACTCTG
R: ACAAACTGCATCGGACTTATC
OPG Full length F: ATGAACAAGTTCCTGTGCTGCA
R: TTAGACACATCTTACTTTCACTGATTTCA
sRANKL Extracellular
domain
F: TGAAGAAGATGGACCCTAGTA
R: TCAGTCTAAATCCCTTACTTTA
sRANK Extracellular
domain
F: ACAAACTGCATCGGACTTATC
R: TCAGTTCAACACCTTCTCA
28S Taqman F: GGCGAAGCCAGAGGAAACT
R: GACGACCGATTTGCACGTC
P: AGGACCGCTACGGACCTCCACCA
IL-1β Taqman F: GCTCTACATGTCGTGTGTGATGAG
R: TGTCGATGTCCCGCATGA
P: CCACACTGCAGCTGGAGGAAGCC
IL-6 Taqman F: GCTCGCCGGCTTCGA
R: GGTAGGTCTGAAAGGCGAACAG
P: AGGAGAAATGCCTGACGAAGCTCTCCA
IL-12α Taqman F: TGGCCGCTGCAAACG
R: ACCTCTTCAAGGGTGCACTCA
P: CCAGCGTCCTCTGCTTCTGCACCTT
RANKL Taqman F: CTGGAACTCGCAAAGTGAACCT
R: TTTCCCATCACTGAACGTCATATTT
P: TGGCATCATAACAAAGGCCAGGCAAAC
RANK Taqman F: GCCATGTCCC AGAGGATACT
R: GCCAATCCCAGAGCTGAACA
P:TGCTTCATCCACTGATGAGTGTAAATCCTGGACCA
OPG Taqman F: ACAGCCAGGCACTCCTGAGA
R: GCTTTTGACAGACTGCTTTGGA
P: CCCAGAGGGATTTTTCTCCAATGAAACG
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been cloned (Hou et al., 2011) and used to designed primers (Table 1).
Total RNA was extracted from either ConA (Sigma-Aldrich, Poole,
UK)-stimulated chicken splenocytes for 4 h or bone marrow cells
using an RNeasy mini kit (QIAGEN, Crawley, UK) following the ma-
nufacturer’s instructions. First strand synthesis used Superscript III
(Invitrogen). After denaturation of the reverse transcriptase at 70 °C
for 15 min, 1 μl of the reaction was used in a 50 μl volume poly-
merase chain reaction (PCR) containing 10 pmol of each primer, 1 μM
dNTP and 0.625 U of Taq DNA polymerase (Invitrogen). Each cDNA
was cloned into pGEM-T Easy and sequences conﬁrmed from three
independent clones on each strand. The cDNA sequences of chRANKL
and chRANKwere submitted to Ensembl (Accession nos. LM999949
and LM999950). Sequences from species containing orthologues of
RANKL, RANK and OPG were aligned using CLUSTALX v2.1. The sec-
ondary structure of chRANKL was predicted using PSIPRED v3.0
(http://bioinf.cs.ucl.ac.uk/psipred/).
2.2. Sub-cloning of chRANKL, chRANK and chOPG into
expression vectors
To obtain soluble forms of chRANKL (schRANKL) and chRANK
(schRANK), their extracellular domains were identiﬁed using their
human orthologues and the SMART prediction program
(http://smart.embl-heidelberg.de/). Primers containing restriction
enzyme sites were designed to ﬂank the extracellular domains of
chRANKL and chRANK (Table 1). To obtain schRANKL, the extracel-
lular domain was ampliﬁed and sub-cloned into the NhoI and NheI
sites of a modiﬁed pCI-neo vector (Promega, Southampton, UK) ex-
pressing the mouse CD8 signal peptide, an isoleucine zipper and
an NH2-terminal FLAG-tag, named pCI-IZFLAG-schRANKL (gener-
ous gift from John Young, the former Institute for Animal Health,
UK). The obtained schRANK and chOPG, the extracellular domain
of chRANK and the full-length chOPG cDNA were directionally sub-
cloned into two similar plasmids, Signal-pKW06 and pKW06 (Staines
et al., 2013), to generate COOH-human Fc-tagged recombinant pro-
teins. All sub-cloning was veriﬁed by sequencing.
2.3. Chicken tissues and cells
Tissueswere removed from three 6-week-old J-line chickens (The
Roslin Institute,UK)post-mortem. Tissues takenwere theheart, kidney,
liver,muscle, lung, brain, skin, spleen, thymus, bursaof Fabricius, caeca,
bonemarrow, crop, gizzard, lowerandmid-gut, caecal tonsils,Meckel’s
diverticulum andHarderian gland. Tissueswere homogenised using
matrix tubes containing 1.4 mm ceramic spheres (MD Biomedicals).
Primary cell populationswereprepared fromthe spleen, bursa of Fab-
ricius and thymus of three individual birds. Cells were puriﬁed by
passing the tissues through 70 μm mesh cell strainers (Fisher Sci-
entiﬁc) and splenocyteswere collectedoverHistopaque-1077 (Sigma-
Aldrich) followedby twowasheswithPBS.Cell numberswereadjusted
to 5 × 106 cells/ml with pre-warmed complete RPMI (10% chicken
serum (ChS), 2% L-glutamine, 1 U/ml penicillin and 1 μg/ml strep-
tomycin (Gibco Life Technologies)) and cultured in 25mm2 ﬂasks for
24 heitherunstimulatedor stimulatedas follows: splenocytes, 1 μg/ml
ConA (Sigma-Aldrich); bursal cells, 500 ng/ml PMA (Sigma-Aldrich)
and 1 μg/ml ionomycin (Sigma-Aldrich); thymocytes, 25 μg/ml PHA
(Sigma-Aldrich). Lymphocyte subsets (CD4+, CD8β+, TCRγδ+, TCRαβ1+
and TCRαβ2+) were isolated from total splenocytes by positive se-
lection using an AutoMACS Pro Separator (Miltenyi Biotech). Purity
of the isolated populations was veriﬁed by FACS analysis (BD
FACSCalibur, BDBiosciences). Todetermine the transcriptional regula-
tionof chRANK inavian splenocytes, cellswereunstimulatedor stimu-
lated with ionomycin (3 μg/ml) or ionomycin and PMA (500 ng/ml)
for 2, 4 or 18 h. To determine if Ca+2 modulation was linked with
chRANKL transcriptional regulation, cellswere either stimulatedwith
ionomycin alone or in combination with various amounts of the
pharmacological inhibitor of Ca2+mobilisation, 8-(diethylamino)octyl-
3,4,5-trimethoxybenzoate (TMB-8) (Sigma-Aldrich) for 18 h.
2.4. Protein production
COS-7 cells were routinely grown and passaged in complete
DMEM (10% FCS, 2% L-glutamine, 2% non-essential aa, 1 U/ml pen-
icillin and 1 μg/ml streptomycin). To produce recombinant protein,
pCI-IZFLAG-schRANKL, Signal-pKW06-schRANK and pKW06-
chOPGwere transfected into COS-7 cells using DEAE-dextran (Avery
et al., 2004). Cell supernatants (ex-COS-7) were collected 72 h later
and stored at 4 °C until use.
2.5. Western blot analysis
The supernatants from COS-7 cells transfected with pCI-IZFLAG-
schRANKL or pKW06-chOPG-Fc were treated with loading buffer
with or without β-mercaptoethanol and boiled for 5 min at 95 °C.
Samples were then loaded on a 4–12% gradient SDS–PAGE gel (Bio-
Rad) and transferred onto nitrocellulose membrane. Samples were
blocked with 2% casein for 1 h at room temperature. FLAG tagged
schRANKL protein was detected using a mouse anti-FLAG mAb
(Sigma-Aldrich, M2) and a goat anti-mouse IgG HRP-conjugated sec-
ondary antibody (SouthernBiotech, 1070-05). ChOPG-Fcwas detected
using a goat anti-human HRP-conjugated antibody (SouthernBiotech,
2040-05). Recombinant protein was detected using an ECLTMWestern
Blotting Detection Reagents system (GE Healthcare Life Sciences,
Little Chalfont, UK).
2.6. BMDC and BMM preparation
Femurs and tibias were collected aseptically from 4 to 6-week-
old J-line chickens. Bone marrow-derived DC (BMDC) and
macrophages (BMM)were expanded in vitro as described inWu et al.
(2010) and Garceau et al. (2010), respectively. In brief, bones were
ﬂushed with PBS and single cell suspensions were collected using
Histopaque-1077 (Sigma-Aldrich) followed by twowashes with PBS.
BMDC were seeded at 1 × 106 cells/ml in 6-well plates in complete
RPMI and cultured with appropriate dilutions of exCOS-7 super-
natants of chIL-4 and chCSF-2. For BMM, cells were seeded at 1 × 106
cells/ml in complete BMM RPMI (2% ChS, 3% FCS, 2% L-glutamine,
1 U/ml penicillin and 1 μg/ml streptomycin) and appropriate dilu-
tions of exCOS-7 supernatants of chCSF-1 in 25-well chamber plates
(Thermo Scientiﬁc). BMDC and BMM were cultured for 6 days at
41 °C, 5% CO2.
2.7. Bioactivity of schRANKL on BMDC and BMM
BMDC and BMM were unstimulated or stimulated with LPS
(1–2 ng/ml), schRANKL (1:50 exCOS-7 supernatant) or both for 3 and
6 h. To determine the antagonistic effects of schRANK-Fc and chOPG-
Fc (1:5exCOS-7supernatant), eitherwaspre-incubatedwithschRANKL
for 3 h prior to cell treatment. The resultingmRNA expression levels
of pro-inﬂammatory cytokines were analysed by qRT-PCR.
2.8. Fluorescent activated cell sorting
On day 6 of BMDC and BMM cultures, cells were unstimulated
or stimulated with LPS (1–2 ng/ml), schRANKL (1:5 exCOS-7 su-
pernatant) or both for 24 h. Cells were removed from culture plates
using 0.05 mM EDTA and resuspended in PBS with 0.5% BSA and
0.001% azide (FACS buffer). Immunoﬂuorescence labellingwas carried
out usingmouse anti-chickenMHC class II (IgG1, 2G11), mouse anti-
chicken CD40 (IgG2a, Serotec, MCA2836) and mouse anti-chicken
KUL01 (IgG1, SouthernBiotech, 8420-01) mAbs on ice for 20 min.
A FITC-conjugated goat anti-mouse IgG1 antibody (SouthernBiotech,
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1070-02) was used as a secondary antibody to detect MHC class II
and KUL01 and a PE-conjugated goat anti-mouse IgG2a antibody
(SouthernBiotech, 1080-09S) to detect CD40, incubated on ice for
20 min. Negative/isotype controls were used for each sample to
control for non-speciﬁc binding. Cells were stained with 7-AAD prior
to analysis and gated using FSC and SSC using a BD FACSCalibur in-
strument (BD Biosciences). Data were analysed using FlowJo v7.6.5
software (Tree Star, Ashland, USA).
2.9. Flow cytometer-based survival assay
BMDC and BMM were treated with fresh complete media or
schRANKL (1:5 exCOS-7 supernatant) for 24 and 48 h. Cellswere har-
vested at indicated time-points and stained with biotin-conjugated
recombinant Annexin-V according to the manufacturer’s instruc-
tions (eBioscience). Conjugated streptavidin-Alexa 657 (Molecular
Probes, S-21374) was incubated at RT for 20min. Propidium iodide
(PI) was added to the cells and immediately analysed using a BD
FACSCalibur instrument.
2.10. Quantitative real-time RT-PCR analysis
RNA from the tissues and cells were extracted using RNeasy Mini
kit (Qiagen, Crawley, UK) following manufacturer’s instructions.
ChRANKL, chRANK and chOPG and pro-inﬂammatory cytokinemRNA
expression levels were quantiﬁed by TaqMan real-time quantita-
tive RT-PCR (qRT-PCR) using a well described method (e.g. Avery
et al., 2004; Eldaghayes et al., 2006). Primers (Sigma) and probes
(Eurogentec, Belgium) (Table 1) were designed using Primer Express
(Applied Biosystems). TaqMan assays were performed using the One-
Step RT-PCR Master Mix reagents and ampliﬁcation and detection
were performed using the FAST Universal PCR Master Mix (Applied
Biosystems). Data are expressed in terms of the cycle threshold (Ct)
value, which is normalised using the Ct values of 28S rRNA for each
sample using the formula; Ct + (N′t-C′t)*(S/S′) where N′t is the mean
Ct value for 28S RNA among all samples, C′t is the mean value for
28S RNA in the sample and the S and S′ are the slopes of regres-
sion of the standard plots for the cytokine mRNA and the 28S RNA,
respectively. Normalised Ct values were corrected against the neg-
ative association of the log concentration of mRNA detected using
the formula 40 – normalised Ct value of the cytokine of interest.
Final results are shown as corrected 40 − Ct values or as fold dif-
ference from levels in untreated control cells.
2.11. Statistical analysis
Statistical analyses were carried out using the Mann–Whitney U
test in Minitab 16.1.0 (State College, USA). Statistical signiﬁcance was
determined as signiﬁcant when (p < 0.05).
3. Results
3.1. Cloning and analysis of chRANKL, chRANK and chOPG
A multiple alignment of the aa sequences of human, mouse and
chicken RANKL is shown in Fig. 1A. ChRANKL shares ~59–62% iden-
tity with mammalian RANKL. The extracellular domains of TNF
superfamily members express the highly conserved TNF homol-
ogy domain (residues 163–318 in the chicken molecule) which is
required for receptor interaction and trimerisation. This domain is
composed of β-strands and loops connected in a “jelly-roll” fold
(Lam et al., 2001). To investigate the conservation of these β-strands
in chRANKL, each was identiﬁed in mammalian RANKL (Fig. 1A)
using PSIPRED. ChRANKL has conserved residues at the positions
of the β-strands and loops found in mammalian counterparts sug-
gesting it has the potential to fold into a trimeric protein. There
are four conserved cysteines between mammalian and chicken
RANKL, and three potential N-glycosylation sites in the chRANKL
extracellular domain, one of which is conserved with mammalian
RANKL.
A multiple alignment of the aa sequences of human, mouse and
chicken RANK is shown in Fig. 1B. ChRANK has ~40–42% sequence
identity with mammalian RANK. The TNFR superfamily members
have conserved CRD in their extracellular ligand-binding domains
(Naismith and Sprang, 1998), which are typically deﬁned by three
intra-chain disulphide bridges between highly conserved cysteine
residues that act as a scaffold to produce an elongated structure
protruding from the cell (Smith et al., 1994). All four CRD are present
in chRANK (labelled I–IV) and all of the cysteine residues in the CRD
are conserved between the three species. There are two potential
N-glycosylation sites in the extracellular domain of chRANK, both
conserved in the mammalian molecules. All TNFR lack catalytic
domains and require adaptor proteins for downstream signalling,
called TRAFs, which formammalian RANK include TRAF1-3, TRAF5-6.
Two binding motifs for TRAF1-3 and TRAF5 in TNFR have been
identiﬁed; a major one, (P/S/A/T)X(Q/E)E, and a minor one, PXQXXD
(X being any aa) (Devergne et al., 1996; Ishida et al., 1996). The TRAF6
speciﬁc-binding motif is the peptide PXEXX (X being an aromatic or
acidic residue). Four of the ﬁvemammalian RANK TRAF-binding sites
(Cremer et al., 2002; Darnay et al., 1998; Wong et al., 1998) are
conserved in chRANK (Fig. 1B). The “missing” TRAF-binding motif is
TRAF6-speciﬁc (residues 457–463 in huRANK). ChRANK also contains
the highly conserved region (HCR; between Pro508 and Gly546 in
muRANK), which is vital for osteoclastogenesis inmammals (Taguchi
et al., 2009).
To produce soluble protein the extracellular domain of chRANKL
was cloned as a 729 bp cDNA fragment corresponding to 243 aa
(chRANKL75–318) and is henceforth called schRANKL. The extracellular
domain of chRANKwas cloned as a 498 bp cDNA fragmentwhich cor-
responded to166 aa (chRANK24–190) and is henceforth called schRANK.
The full-length chOPG cDNA was cloned using primers designed
based on the NCBI database sequence. Total RNAwas extracted from
bonemarrow and used to amplify a cDNA fragment of 1.2 kb, corres-
ponding to 401 aa. A multiple alignment of the aa sequences of
human, mouse and chicken OPG is shown in Fig. 1C. ChOPG shares
high identity with mammalian OPG (60–64%). It possesses four CRD
domains (labelled I–IV) with 17 out of 18 cysteine residues conserved
and two homologous DD which are conserved between the three
species. ChOPG contains a penultimate cysteine residue at position
401 which is vital for homodimerisation in mammalian OPG (Luan
et al., 2012).
3.2. Soluble chRANKL and chOPG form homo-trimeric and
homo-dimeric protein structures
The hallmark of TNF ligand and TNFR interactions is their
threefold-symmetry. Three subunits of RANKL are required for the
activation of the receptor, RANK. To enhance the formation of tri-
meric schRANKL protein, amodiﬁed plasmidwas designed to express
an in-frame isoleucine zipper sequence upstream of the chRANKL
sequence with an NH2-terminal FLAG-tag, called pCI-IZFLAG-
schRANKL. SchRANKL protein was generated in COS-7 cells and
protein structures were analysed by SDS–PAGE under reducing and
non-reducing conditions and western blot using antibodies against
the FLAG-tag. In reducing conditions, schRANKL appears as pre-
dominantly a monomeric protein at ~37 kDa with a weak band of
~75 kDa which is possibly dimeric protein (Fig. 2). Proteins analysed
under non-reducing conditions produced bands at ~75, ~ 140 and
~200 kDa, suggesting the formation of dimeric, trimeric and pos-
sibly tetrameric protein structures (Fig. 2A).
To analyse the ability of chOPG to form homodimeric protein,
COS-7 cells were transfected with pKW06-chOPG to produce soluble
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chOPG-Fc. Protein structures were analysed under reducing and
non-reducing conditions and visualised by western blot using
antibodies against the Fc tag (Fig. 2). The chOPG-Fc monomer has a
predicted molecular mass of ~72 kDa. In reducing conditions,
a ~ 75 kDa bandwas just evident whereas in non-reducing conditions
there was a strong band at ~160 kDa, suggesting the formation of
homodimers (Fig. 2B).
3.3. Tissue distribution and cellular mRNA expression levels of
chRANKL, chRANK and chOPG
The mRNA expression proﬁles of chRANKL, chRANK and chOPG
were determined in a broad range of non-lymphoid and lymphoid
tissues by qRT-PCR. Primers and probes for chRANKL and chRANK
were designed against their extracellular domains. In both non-
lymphoid and lymphoid tissues, mRNA transcripts for each gene
were detected, suggesting each is ubiquitously expressed in chicken
tissues (Fig. 3).
In non-lymphoid tissues, chRANKL and chRANK mRNA expres-
sion levels are highest in muscle, which had the lowest levels of
chOPG mRNA expression (Fig. 3A). The lowest levels of chRANKL
and chRANK mRNA expression were in the heart. Levels of mRNA
expression of all three cytokine were consistent in the liver, kidney
and lung and slightly lower in the skin and brain (Fig. 3A). In chicken
lymphoid tissues, the highest levels of mRNA expression for all
three cytokines were in the thymus, followed by the upper-gut and
the bone marrow (Fig. 3B). In the crop, chRANKL mRNA expres-
sion levels were higher (~16-fold) than those of chRANK and chOPG.
In the Harderian gland, chRANKL was more highly expressed than
chRANK.
The mRNA expression levels of chRANKL, chRANK and chOPG
were also examined in ConA stimulated splenocytes, PMA and
A
Human   MRRASRDYTKYLRGSEEMGGGPGAPHEGPLH.APPPPAPHQPPAASRSMFVALLGLGLGQ 59
Mouse   MRRASRDYGKYLRSSEEMGSGPGVPHEGPLHPAPSAPAPAPPPAASRSMFLALLGLGLGQ 60 
Chicken MRRASRDYTKYLRGSEEVGSGAAHESAPPPPPAPPLPAHPHPPPASRSLLAALVLLGLGQ 60
Human   VVCSVALFFYFRAQMDPNRISEDGTHCIYRILRLHENADFQDTTLESQDTKLIPDSCRRI 119
Mouse   VVCSIALFLYFRAQMDPNRISEDSTHCFYRILRLHENADLQDSTLESEDT..LPDSCRRM 118
Chicken VVCSVALFLYFRAQMDPSRISKEDAHCVRMLFRSQESIGLQDTPFENQEVKLMPESCRRM 120
          *                       *                             * 
Human   KQAFQGAVQKELQHIVGSQHIRAEKAMVDGSWLDLAKRSKLEAQPFAHLTINATDIPSGS 179
Mouse   KQAFQGAVQKELQHIVGPQRFSGAPAMMEGSWLDVAQRGKPEAQPFAHLTINAASIPSGS 178
Chicken KRALQRAVQKEVQRILGKESPRPEKAAMEAIGMELYRRNKPEKQPFAHLIIDDKNILTGT 180
Human   HKVSLSSWYHDRGWAKISNMTFSNGKLIVNQDGFYYLYANICFRHHETSGDLATEYLQLM 239
Mouse   HKVTLSSWYHDRGWAKISNMTLSNGKLRVNQDGFYYLYANICFRHHETSGSVPTDYLQLM 238
Chicken RKVNLTSWHHNKGQANLSNMTFSDGKLIVNQDGFYYLYANICFRHHETSGNLTKRGLQLM 240
           +++            +++                       *     +++ 
Human   VYVTKTSIKIPSSHTLMKGGSTKYWSGNSEFHFYSINVGGFFKLRSGEEISIEVSNPSLL 299
Mouse   VYVVKTSIKIPSSHNLMKGGSTKNWSGNSEFHFYSINVGGFFKLRAGEEISIQVSNPSLL 298
Chicken VYMTKTNLKIRRSDVLMKGGSTKYWSGNSEFHFYSVNIGGFLKLKTGDMISIQVSNPLLL 300
Human   DPDQDATYFGAFKVRDID 317 
Mouse   DPDQDATYFGAFKVQDID 316 
Chicken DSSQEATYFGAFKVRDLD 318 
A AA’ loop
DB’B’A
CD loop 
DE loop EF loop GFE
C
H
Fig. 1. Alignment of the sequences of RANKL, RANK and OPG. Amino acid sequence alignment of (A) chRANKL, (B) chRANK and (C) chOPG with their mammalian orthologues.
Shaded areas represent conservation of aa; the darker the shading, the more conserved the residue across species. Dots indicate gaps in the alignment. Asterisks indicate
conserved cysteine residues. Predicted N-glycosylation sites in any molecule are indicated by +++. (A) RANKL is a type II membrane protein. The box indicates the trans-
membrane domains. The TNF homology domain is underlined. Black lines above the sequences indicate the location of the ten conserved β-strands (labelled A, A′, B′, B, C,
D, E, F, G and H) involved in the “β-jelly” roll structure, and the surface loops are shown as grey lines between the β-strands, labelled AA′, CD, DE and EF (based on the
mouse RANKL crystal structure (Lam et al., 2001). (B) The four CRD domains are overlined and numbered I–IV, the black box indicates the transmembrane domain and the
light grey box the HCD. TRAF-binding motifs are overlined and labelled (6 = TRAF6, 1/2/3/5 = TRAF1, TRAF2, TRAF3, TRAF5 binding motifs). (C) The four CRD domains are
overlined and numbered I–IV, the DD are overlined and the triangle indicates the conserved cysteine residue in mammals not conserved in the chicken.
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ionomycin stimulated bursal cells and PHA stimulated thymo-
cytes (Fig. 4A). After 24 h of stimulation the mRNA expression levels
of chRANKL, chRANK and chOPG were not statistically signiﬁ-
cantly altered compared to levels in unstimulated cells (Fig. 4A). At
a cellular level, the mRNA expression levels of all three molecules
were detected in CD4+, CD8β+, TCRγδ+ and TCRαβ+ cells (Fig. 4B).
3.4. ChRANK and chOPG mRNA are differentially expressed in
mature BMDC
In mammals, RANK surface expression is predominantly found
on mature DC and osteoclasts (Anderson et al., 1997; Wong et al.,
1997b) while OPG expression is in osteoblasts (Yasuda et al., 1998),
B
Human   MAPRARRRRPLFA-LLLLCALLAR-LQVALQIAPPCTSEKHYEHLGRCCNKCEPGKYMSS  58 
Mouse   MAPRARRRRQLPAPLLALCVLLVP-LQVTLQVTPPCTQERHYEHLGRCCSRCEPGKYLSS  59 
Chicken -MPGP------PGWLALLCLAAAGRPQLSLQSTLPCESEQHYEYSGRCCKKCEPGKYMSA  53 
                          *                *           **  * 
Human   KCTTTSDSVCLPCGPDEYLDSWNEEDKCLLHKVCDTGKALVAVVAGNSTTPRRCACTAGY 118 
Mouse   KCTPTSDSVCLPCGPDEYLDTWNEEDKCLLHKVCDAGKALVAVDPGNHTAPRRCACTAGY 119 
Chicken KCTETSDSVCQPCGPNEYMDVWNEEDKCLLHKICDQGKALKEVNPGNSTFQRQCACTTGY 113 
         *       *  *              *     *            +++    * *
Human   HWSQDCECCRRNTECAPGLGAQHPLQLNKDTVCKPCLAGYFSDAFSSTDKCRPWTNCTFL 178 
Mouse   HWNSDCECCRRNTECAPGFGAQHPLQLNKDTVCTPCLLGFFSDVFSSTDKCKPWTNCTLL 179 
Chicken HWNEDCDCCQRNSICGPGFGIGHPVQQDKDTKCMPCPRGYFSEVASSTDECKSWTNCSAL 173 
             * **     *                 *  *              *     * 
Human   GKRVEHHGTEKSDAVCSSSLPARKPPNEPHVYLPGLIILLLFASVALVAAIIFGVCYRKK 238 
Mouse   GKLEAHQGTTESDVVCSSSMTLRRPPKEAQAYLPSLIVLLLFISVVVVAAIIFGVYYRKG 239 
Chicken GLAEIVPGTDKSDAVCSKQKMAEQPEYGTNKILYVFIVILFFV--ALIGIVIFIVYYKNK 231 
                       *            
Human   GKALTANLWHWINEACGRLSGDKESSGDSCVSTHTANFGQQGACEGVLLLTLEEKTFPED 298 
Mouse   GKALTANLWNWVNDACSSLSGNKESSGDRCAGSHSATSSQQEVCEGILLMTREEKMVPE- 298 
Chicken GKKLTADLQNWANEVCSQIKGTKEPSRDAYVTVNITNTTIPQLSEDVRLLGPAGSPAPG- 290 
                       *                 ++++++        
Human   MCYPDQGGVCQGTCVGGGP-YAQGEDARMLSLVSK-TEIEEDSFRQMPTEDEYMDRPSQP 356 
Mouse   ----DGAGVCGPVCAAGGP-WAEVRDSRTFTLVSE-VETQGDLSRKIPTEDEYTDRPSQP 352 
Chicken -----SSPCGHSSCRHGSPGTAPCRAGGNLQEVSVGTGTDDEHFSPVPTEDEYMDKDLNT 345 
                *    *         *                      
Human   TDQLLFLTEPGSKSTPPFSEPLEVGENDSLSQCFTGTQSTVGSESCNCTEPLCRTDWTPM 416 
Mouse   STGSLLLIQQGSKSIPPFQEPLEVGENDSLSQCFTGTESTVDSEGCDFTEPPSRTDSMPV 412 
Chicken ADYLPLLSQPDNKTLSLFSEPVEVGENDSLNQCFSGIGSAEDVSMPQGSDPSSNADGVHT 405 
                   +++            +++   *               
Human   SSENYLQKEVDSGH-CPHWAASPS-------PNWADVCTGC----RNPPGEDCEPLVG-- 462 
Mouse   SPEKHLTKEIEGDS-CLPWVVSS---------NSTDGYTGS----GNTPGEDHEPFPG-- 456 
Chicken TMDKYLQKSCQRSHGCPKEIDSKDTDRFAMNRDSEKICVRCGVSYRETPRKGSRPCCAAV 465 
                 *     *                     *  *              ** 
Human   -----SPKRGPLPQCAYGMGLPPEEEASRTEAR---DQPEDGADGRLPSSARAGAGSGSS 514 
Mouse   -----SLKCGPLPQCAYSMGFPSEAAASMAEAG---VRPQDRAD------ERGASGSGSS 502 
Chicken DGAFTSPETGCYAQCTCGMNFLSAGQSPLASDHGMEDAPSDGTNTKYQNTNRSTSGTNSS 525 
                  *   * *                                 +++    +++ 
Human   PGGQSPASGNVTGNSNSTFISSGQVMNFKGDIIVVYVSQTSQEG---AAAAAEPMGRPVQ 571 
Mouse   PSDQPPASGNVTGNSNSTFISSGQVMNFKGDIIVVYVSQTSQEGPGSAEPESEPVGRPVQ 562 
Chicken TSDLPPASGNVTGNSNSTFISSGQVMNFKGDIIVVYLSQNSQEGAAASGAAEENVSSPVQ 585 
                 +++   +++                                   +++ 
Human   EETLARRDSFAGNGPRFPDPCG--------GPEGLREP----------EKASRPVQEQGG 613 
Mouse   EETLAHRDSFAGTAPRFPDVCA--------TGAGLQEQGAPR----QKDGTSRPVQEQGG 610 
Chicken EENPSRCETFAGNAQHYKEKCAELHATIPVGSGGTRHHTAPVPSLARHSEASPPVQEEGR 645 
              *             *
Human   AKA------------ 616 
Mouse   AQTSLHTQGSGQCAE 625 
Chicken LGHSSEKVLN----- 655 
I
II
IIII V
6
6
6
1/2/3/5 
1/2/3/5 
+++
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suggesting a role for the latter in regulating the interaction between
RANKL–RANK in bone metabolism. OPG in human Mo-DC has a
similar role, where OPG expression levels increase as DC mature
(Schoppet et al., 2007), suggesting that OPG is also amolecular brake
for RANKL–RANK interactions in the immune system. Before ex-
amining the bioactivity of schRANKL, the mRNA expression levels
of both of its receptors were analysed in BMDC. BMDC were
unstimulated or stimulated with various concentrations of LPS for
3, 6 and 9 h and mRNA expression levels of the two receptors
analysed by qRT-PCR.
At 3 h, LPS-stimulated (200 ng/ml) cells had a ~ 2-fold increase
in chRANK and chOPG mRNA expression levels which dropped to
~1-fold at the lower amounts of LPS used, compared to levels in
unstimulated cells (Fig. 5). At 6 h post-stimulationwith high LPS con-
centrations, chOPGmRNA expression levels were increased by nearly
3-fold while levels of chRANK mRNA expression were only in-
creased by ~0.5-fold. At lower concentrations of LPS, chRANKmRNA
expression levels decreased to basal unstimulated levels or lower
(Fig. 5). Cells stimulated with 100 ng/ml of LPS increased chOPG
mRNA expression levels statistically signiﬁcantly compared to
chRANKmRNA expression levels (p < 0.05). At 9 h, chOPGmRNA ex-
pression levels were statistically signiﬁcantly higher compared to
chRANKmRNA expression levels in all LPS-stimulated cells (p < 0.05).
C
Human   MNNLLCCALVFLDISIKWTTQETFPPKYLHYDEETSHQLLCDKCPPGTYLKQHCTAKWKT  60
Mouse   MNKWLCCALLVLLDIIEWTTQETLPPKYLHYDPETGHQLLCDKCAPGTYLKQHCTVRRKT  60
Chicken MNKFLCCTLVLLDISVKWSIQDISPPKYLHYDPGTSRQVMCNQCPPGSYVKQHCTAASPT  60
             **                                 *  *         *
Human   VCAPCPDHYYTDSWHTSDECLYCSPVCKELQYVKQECNRTHNRVCECKEGRYLEIEFCLK 120
Mouse   LCVPCPDHSYTDSWHTSDECVYCSPVCKELQSVKQECNRTHNRVCECEEGRYLEIEFCLK 120
Chicken VCAPYPDQYYAEDWNSNDECQYCSAVCKELQYIKQECTSTQDRVCECIEGWYLELEFCLK 120
         *                 *  *   *         *+++    * *          * 
Human   HRSCPPGFGVVQAGTPERNTVCKRCPDGFFSNETSSKAPCRKHTNCSVFGLLLTQKGNAT 180
Mouse   HRSCPPGSGVVQAGTPERNTVCKKCPDGFFSGETSSKAPCIKHTNCSTFGLLLIQKGNAT 180
Chicken HTECPPGFGVAQPGTPESDTVCKSCPEGFFSNETSSKAVCQKHTNCSALGFKTALKGNAV 180
           *                 *  *      +++     *     *           +++
Human   HDNICSGNSEST.QKCGIDVTLCEEAFFRFAVPTKFTPNWLSVLVDNLPGTKVNAESVER 239
Mouse   HDNVCSGNREAT.QKCGIDVTLCEEAFFRFAVPTKIIPNWLSVLVDSLPGTKVNAESVER 239
Chicken RDNICQENTDTSPQKCGIDITLREEAMFRFAVPTRSTPNWLNTLADNLPGTKISTENIER 240
            *                 Δ
Human   IKRQHSSQEQTFQLLKLWKHQNKDQDIVKKIIQDIDLCENSVQRHIGHANLTFEQLRSLM 299
Mouse   IKRRHSSQEQTFQLLKLWKHQNRDQEMVKKIIQDIDLCESSVQRHLGHSNLTTEQLLALM 299
Chicken IKQRHSSQEQTFQLLKLWKQQNKEQDMVKKIIQDIDHCENSVLKHLGQPSLTFEHLNTLM 300
                                             *           +++
Human   ESLPGKKVGAEDIEKTIKACKPSDQILKLLSLWRIKNGDQDTLKGLMHALKHSKTYHFPK 359
Mouse   ESLPGKKISPEEIERTRKTCKSSEQLLKLLSLWRIKNGDQDTLKGLMYALKHLKTSHFPK 359
Chicken ASLPGKKVGKEDIERTMKLCQHAEQVLKLLNLWRIKNGDQDTIKGLMYGLKHLKTYHFPK 360
                           * 
Human   TVTQSLKKTIRFLHSFTMYKLYQKLFLEMIGNQVQSVKISCL 401 
Mouse   TVTHSLRKTMRFLHSFTMYRLYQKLFLEMIGNQVQSVKISCL 401 
Chicken RIIQSLKKVIKFLHGFAMYRLYQKLFLEMVGSQLKSVKVRCV 402 
                                                *
I
II III 
IV
+++
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Fig. 2. Western blot analyses of schRANKL and chOPG proteins. The extracellular
soluble domain of chRANKL (schRANKL) was sub-cloned into a modiﬁed pCI-neo
vector, expressing an NH2-terminal FLAG-tag and an in-frame isoleucine zipper se-
quence to encourage trimer formation. ChOPG was sub-cloned into a pKW06 vector
and expressed as a human Fc-tagged protein. Samples were analysed under reduc-
ing (R) and non-reducing (NR) conditions. Marker (M) = protein precision plus
(BioRAD).
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3.5. Transcriptional control of chRANKL mRNA expression in avian
splenocytes
Our previous data have shown that ConA stimulation has no effect
on chRANKL mRNA expression in chicken splenocytes. Therefore,
to further understand the regulation of chRANKL transcription,
splenocytes were activated with the Ca2+-mobiliser/inducer,
ionomycin or ionomycin and the PKC activator, PMA, to mimic the
signals initiated by TCR activation for 2, 4 and 18 h. Levels of
chRANKL mRNA expression were analysed by qRT-PCR (Fig. 6).
At 2 h post-stimulation with ionomycin alone, chRANKL mRNA
expression levels were unaltered compared to those in unstimulated
cells whereas costimulated cells had a ~ 3-fold, but not signiﬁcant
increase in chRANKL mRNA expression levels (Fig. 6A). At 4 h,
ionomycin-stimulated cells statistically signiﬁcantly increased
chRANKL mRNA expression levels by ~5-fold compared to levels in
unstimulated cells (p < 0.05). The addition of PMA in costimulated
cells did not increase chRANKL mRNA expression levels any further.
At 18 h, chRANKL mRNA expression levels in ionomycin-stimulated
cells again were not statistically signiﬁcantly different from levels
in unstimulated controls. This could suggest that ionomycin-
mediated Ca2+-mobilisation declines over time and no longer induces
chRANKL mRNA expression. At 18 h, chRANKL mRNA expression
levels were statistically signiﬁcantly increased in costimulated cells
compared to ionomycin-only stimulated cells and unstimulated cells
(p < 0.05), indicating that the concomitant activation of Ca2+-
mobilisation and the PKC pathway are necessary to drive the
transcription of chRANKL in chicken splenocytes, after at least 4 h
of co-stimulation.
To verify that the transcriptional regulation of chRANKL was
linked to the activation and mobilisation of Ca2+, splenocytes were
stimulated with ionomycin or ionomycin with various concentra-
tions of the Ca2+ channel and PKC inhibitor, TMB-8. The levels of
chRANKL mRNA expression were analysed in these cells after 18 h
of treatment by qRT-PCR (Fig. 6B), and the addition of TMB-8 at all
three concentrations reduced chRANKL mRNA expression levels to
those in unstimulated cells.
3.6. The effects of chRANKL on mRNA expression levels of
pro-inﬂammatory cytokines in BMDC and BMM
To examine the bioactivity of schRANKL on BMDC, recombi-
nant protein (schRANKL fused to FLAG) was produced in COS-7 cells
and its effect on pro-inﬂammatory cytokine expression by BMDC
was determined. On day 6 of culture, BMDC were unstimulated or
stimulated with LPS, schRANKL or both, for 3 and 6 h. mRNA ex-
pression levels of the pro-inﬂammatory cytokines, IL-1β, IL-6 and
IL-12α, were analysed by qRT-PCR (Fig. 7A).
At both time-points, LPS-stimulated cells had upregulated IL-
12αmRNA expression levels. Stimulation with schRANKL on its own
did not induce IL-12αmRNA expression and costimulation with LPS
did not affect IL-12α mRNA expression levels compared to those in
cells stimulated only with LPS. IL-12α mRNA expression was not
detected in unstimulated cells, and therefore these data are pre-
sented as corrected 40-Ct and not as fold change.
At 3 h, IL-1βmRNA expression levels were signiﬁcantly increased
(26-fold) in LPS-stimulated cells (Fig. 7A) compared to those in
unstimulated cells (p < 0.05). Costimulated cells also had a signiﬁcant
increase in IL-1β mRNA expression levels compared to those in
unstimulated cells (p < 0.05) but were not statistically signiﬁcantly
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Fig. 3. ChRANKL, chRANK and chOPG mRNA expression in chicken tissues. Expres-
sion proﬁles of chRANKL, chRANK and chOPGmRNA in non-lymphoid and lymphoid
tissues, as measured by qRT-PCR. (A) Non-lymphoid tissues: (1) brain, (2) muscle,
(3) heart, (4) liver, (5) kidney, (6) lung, (7) skin. (B) Lymphoid tissues: (1) thymus,
(2) spleen, (3) bursa of Fabricius, (4) caecal tonsil, (5) Harderian gland, (6) bone
marrow, (7) Meckel’s diverticulum, (8) caeca, (9) mid-gut, (10) upper-gut, (11) crop,
(12) gizzard. Data are presented as the average corrected 40-Ct values of triplicate
assays on each of three individual birds ± SEM.
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Fig. 4. ChRANKL, chRANK and chOPG mRNA expression in chicken immune cells.
ChRANKL, chRANK and chOPG mRNA expression in lymphoid cells, as measured by
real-time qRT-PCR. (A) Expression levels of chRANKL, chRANK and chOPG in ConA
stimulated splenocytes, PMA and ionomycin stimulated bursal cells and PHA stimu-
lated thymocytes for 24 h. Data are presented as fold change in comparison to levels
in unstimulated control cells of triplicate assays on each of three individual birds ± SEM.
(B) Sorted splenocytes. Data are presented as the average corrected 40-Ct values of
triplicate assays on each of three individual birds ± SEM.
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higher than those in LPS-stimulated cells (Fig. 7A). At 6 h, LPS-
stimulation led to a signiﬁcant (~52-fold) increase in IL-1β mRNA
expression levels which were further statistically signiﬁcantly
increased to ~79-fold in co-stimulated cells compared to levels in
unstimulated cells (p < 0.05) and statistically signiﬁcantly higher
than levels in LPS-stimulated cells (p < 0.05) (Fig. 7A). Treatment with
schRANKL alone increased the mRNA expression levels of IL-1β at
6 h but this was not statistically signiﬁcant compared to levels in
unstimulated cells.
At 3 and 6 h, IL-6 mRNA expression levels were signiﬁcantly in-
creased in LPS- and co-stimulated cells compared to levels in
unstimulated cells (p < 0.05) (Fig. 7A). At 6 h, IL-6 mRNA expres-
sion levels in co-stimulated cells were signiﬁcantly increased
compared to those in LPS-stimulated cells (p < 0.05), suggesting that
schRANKL enhances IL-6 mRNA expression in BMDC. Cells treated
with schRANKL alone had a non-signiﬁcant increase (~5-fold) in IL-6
mRNA expression levels at 3 h but there was no increase at 6 h
(Fig. 7A).
Antagonistic effects of schRANK-Fc and chOPG-Fc were deter-
mined by their ability to inhibit the schRANKL-mediated
upregulation of pro-inﬂammatory cytokines in BMDC. SchRANKL
was pre-incubated with schRANK-Fc or chOPG-Fc for 3 h prior to
stimulation of cells and IL-1β, IL-6 and IL-12α mRNA expressions
levels were analysed (Fig. 7A). Incubation of schRANKL with either
schRANK-Fc or chOPG-Fc prior to co-culture with LPS resulted in
statistically signiﬁcantly lower pro-inﬂammatory mRNA expres-
sion levels than those induced by co-culture with LPS and schRANKL
(Fig. 7A). Therefore, pro-inﬂammatory cytokine mRNA expression
levels induced by schRANKL in costimulated cells were inhibited
by the addition of schRANK-Fc and chOPG-Fc.
The bioactivity of schRANKL on BMM was also determined by
examining pro-inﬂammatory cytokine mRNA expression levels
(Fig. 7B). Cells were unstimulated or simulated with LPS, schRANKL
or both, for 3 and 6 h, similarly to BMDC. IL-12α mRNA expression
levels were not detected in any sample (data not shown). At 3 h,
LPS-stimulated cells increased IL-1β mRNA expression levels sig-
niﬁcantly by ~50-fold compared to those in unstimulated cells
(p < 0.05) (Fig. 7B). SchRANKL treatment alone had no effect. Co-
stimulation with LPS and schRANKL did not increase IL-1β mRNA
expression levels further than LPS stimulation alone. At 6 h, IL-1β
mRNA expression levels were still upregulated in LPS-stimulated
cells but at a lower level than at 3 h. SchRANKL treatment alone again
had no effect. Co-stimulated cells increased IL-1β mRNA expres-
sion levels but levels were not statistically signiﬁcantly higher than
those in unstimulated or LPS-stimulated cells.
IL-6 mRNA expression levels were increased in LPS and co-
stimulated cells at both 3 and 6 h but levels were not statistically
signiﬁcantly compared to unstimulated cells, and co-stimulation did
not increase IL-6 mRNA expression levels higher than those in LPS-
stimulated cells (Fig. 7B).
3.7. Cell surface marker expression of BMDC and BMM treated
with schRANKL
To investigate the ability of schRANKL to enhance the expres-
sion of cell surface markers on BMDC and BMM, cells were treated
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Fig. 5. Expression of chOPG and chRANKL in stimulated BMDC. Expression levels of chOPG and chRANKmRNA in BMDC following stimulation with LPS (200, 100 and 1 ng/ml)
for 3, 6 and 9 h. Data are presented as fold change in comparison to levels in unstimulated control cells of triplicate assays on each of three individual birds ± SEM. *p < 0.05
as indicated (Mann–Whitney U test).
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Fig. 6. Transcriptional regulation of chRANKL in chicken splenocytes. ChRANKLmRNA
expression levels were analysed by qRT-PCR in (A) splenocytes stimulated with
ionomycin (3 μg/ml), or ionomycin and PMA (500 ng/ml) for 2, 4 and 18 h and (B)
splenocytes stimulated with ionomycin (3 μg/ml) or ionomycin and TMB-8 (10, 20
or 50 μM) for 18 h. Data are presented as fold change in comparison to levels in
unstimulated control cells of triplicate assays on three individual birds ± SEM. *p < 0.05
compared to unstimulated control cells and #p < 0.05 as indicated (Mann–Whitney
U test).
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with LPS (1–2 ng/ml), schRANKL (1:5 exCOS-7) or both, for 24 h
(Fig. 8). Cells were removed from culture plates and stained for the
chicken mononuclear phagocyte marker, KUL01 (Mast et al., 1998),
and activation markers of chicken APC: MHC class II and CD40 (Wu
et al., 2010).
Co-stimulation of BMDC with LPS, schRANKL or both did not
increase the cell surface expression levels of MHC class II. CD40 cell
surface expression levels were increased in LPS-stimulated cells but
were not enhanced by addition of schRANKL (Fig. 8A). The
expression of KUL01 on the surface of BMDC decreases as the cells
mature (Wu et al., 2010) and this is evident in the LPS-stimulated
BMDC where there were lower cell surface expression levels of
KUL01 than on the control cells (Fig. 8B). SchRANKL had no effect
on cell surface expression of KUL01 when compared to the control
BMDC. Co-stimulated cells had similar cell surface expression levels
of KUL01 as the LPS-stimulated cells (Fig. 8A).
Similarly to BMDC, MHC class II expression levels were not in-
creased by stimulation of BMM with LPS (1 ng/ml) or schRANKL,
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either alone or in combination (Fig. 8B). CD40 cell surface expres-
sion levels were increased in LPS-stimulated BMM but were not
enhanced by the addition of schRANKL (Fig. 8B), which by itself had
no effect. KUL01 cell surface expression levels were decreased in
LPS-stimulated and co-stimulated BMM compared to unstimulated
or schRANKL-stimulated BMM (Fig. 8B).
3.8. Survival of BMDC and BMM treated with schRANKL
To examine whether chRANKL was a survival factor for BMDC
and BMM, cells were treated with or without schRANKL (1:5 exCOS-
7) for 24 and 48 h (Fig. 9). Cell death and apoptosis were measured
by annexin-V and PI staining and analysed by FACS.
After 24 h, 44.7% of untreated BMDCwere viable (annexin-V− PI−)
and 55.3% positive for annexin-V (annexin-V+ PI+) (Fig. 9). This in-
dicates that over half of the cell population analysed under normal
conditions was undergoing apoptosis. In contrast, schRANKL-
treated cells had 57.7% viable cells and 27.8% undergoing apoptosis.
After 48 h, the number of viable untreated BMDC fell to 29% in com-
parison to schRANKL-treated cells where 40% were viable (Fig. 9).
Cells undergoing apoptosis in untreated cells increased to 58.4% but
for schRANKL-treated cells apoptotic cells were 49.8% (Fig. 9). Overall
the data suggest that schRANKL acts as a survival factor for chicken
BMDC.
After 24 h, untreated BMM had a very low number of viable cells
(16.1%) whereas for schRANKL-treated BMM viability numbers were
32.2%. Cells undergoing apoptosis were lower in chRANKL-treated
cells (61.2%) compared to untreated cells (77.9%) (Fig. 9). A further
24 h of cell culture resulted in similar numbers of viable and
apoptotic cells between untreated and schRANKL-treated BMM.
SchRANKL can enhance the survival of BMM at 24 h of stimula-
tion but this enhanced survival is short-lived, as cells begin to
undergo similar rates of apoptosis after 48 h.
4. Discussion
In mammals, the majority of TNF superfamily members are
present as small loci of two or three genes on different chromo-
somes – the chicken lacks three of these small sub-families: LT-α,
TNF-α and LT-β (TNFSF1-3); 4-1BBL, CD27L and LIGHT (TNFSF9, 7
and 14); TWEAK and APRIL (TNFSF12 and 13) (Kaiser et al., 2005).
It has been hypothesised that the lack of lymph nodes in the chicken
is due to the absence of the lymphotoxin genes. Mice lacking some
of the other missing genes in the chicken have defective T and B
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cell responses (Locksley et al., 2001). The absence of the other TNF
superfamily members has not yet been linked to any abnormal de-
velopment or obvious difference in the chicken’s ability to mount
an immune response. However, it is therefore important to study
the biological function of those chicken TNF superfamily members
that are present in more detail.
Mammalian RANKL is a type II transmembrane protein that can
function as either a membrane-bound or secreted form (Ikeda et al.,
2001; Walsh et al., 2013), with no known functional difference
between the two (Nakashima et al., 2000). An aa alignment of full-
length chRANKL with those of human and mouse showed high
conservation across all species. The RANKLmonomer consists of two
anti-parallel β-sheets which are formed by various β-strands (Lam
et al., 2001). Using the PSIPRED prediction program, the locations
of the residues involved in β-sheet formation in chRANKLwere found
to be conserved. SchRANKL contains ten β-strands and the four loops
required for assembly of a homotrimer (Fig. 1A). To investigate the
ability of schRANKL to form homotrimers, the extracellular domain
of chRANKL was sub-cloned into a modiﬁed vector expressing an
in-frame isoleucine zipper previously shown to enhance the bio-
activity of members of the TNF superfamily by encouraging and
stabilising trimeric protein structures (Kim et al., 2004; Morris et al.,
1999). SchRANKL protein structures were analysed under both re-
ducing and non-reducing conditions (Fig. 2) and the data suggest
that schRANKL forms homotrimeric protein structures, a signa-
ture of TNF superfamily members.
Human and mouse OPG cDNAs encode a 401 aa protein that is
further processed to form a 380 aa mature protein. OPG is
synthesised as a glycosylated 55 kDa protein which self-associates
to form disulphide-linked dimers prior to secretion from cells.
ChOPG was previously cloned by Hou et al. (2011). However, no
sequence alignment or analysis was presented in that study to
investigate the conservation of the CRD, DD and penultimate
cysteine residue required for OPG dimer assembly (Simonet et al.,
1997). An aa alignment of chOPG with those of human and mouse
showed it to be highly conserved (64–65% aa identity). ChOPG,
similar to mammalian OPG, naturally forms soluble homodimeric
proteins (Fig. 2).
ChRANKL, chRANK and chOPG mRNA expression levels were
ubiquitous across a range of lymphoid and non-lymphoid tissues
(Fig. 3) and immune cells (Fig. 4) in the chicken. In the bonemarrow,
all three molecules were highly expressed at the mRNA level, which
was not surprising as all three have vital roles in bone metabolism
in mammalian species (Simonet et al., 1997; Yasuda et al., 1998).
In non-lymphoid organs, chRANKL and chRANK mRNA expression
levels were highest in muscle, similarly to mammalian RANKL and
RANK (Anderson et al., 1997; Wong et al., 1997a). The heart had
the lowest mRNA expression levels of all three molecules amongst
the non-lymphoid tissues examined.
In the upper gut, levels of chRANKLmRNA expression were high.
In the mammalian gut-associated lymphoid tissues (GALT), sam-
pling of lumenal pathogens is achieved by M cells (Mabbott et al.,
2013). M cells are highly eﬃcient phagocytic cells that uptake bac-
terial antigen from the lumen into the Payer’s patches, priming CD4+
T cells and IgA+-committed B cells (VanCott et al., 1996). Inmammals,
RANKL is necessary for the differentiation of RANK-expressing
enterocytes into M cells (Knoop et al., 2009). Recently the gener-
ation of CSF1 transgenic chickens identiﬁed the large number of
macrophages in the chicken gut (Balic et al., 2014) therefore it would
be interesting to determine if the high levels of chRANKL mRNA ex-
pressed in the upper gut correlated with the presence of large
numbers of M cells in this tissue.
The expression of both RANK and OPG has been observed on
mature DC in mammals (Anderson et al., 1997; Wong et al., 1997a;
Yasuda et al., 1998). To investigate the expression patterns of the
chRANKL receptors on chicken BMDC, BMDC were generated and
then unstimulated or stimulated with various concentrations of LPS
and the levels of chRANK and chOPG mRNA expression analysed
by qRT-PCR (Fig. 5). The data suggest that themRNA expression levels
of chRANK and chOPG in BMDC are both dose- and time-dependent.
The more the BMDCmatured, the lower the levels of chRANKmRNA
expression and the higher the levels of chOPGmRNA expression ob-
served. Mammalian OPG expression is dependent on activation of
the NF-κB pathway and increases as DC mature (Schoppet et al.,
2007). It is therefore possible that mature chicken BMDC increase
levels of chOPG expression to regulate the magnitude of chRANKL+
T cells interacting with chRANK+ DC and chOPG is therefore a po-
tential marker for mature chBMDC.
The expression of RANKL by mammalian T cells is induced by
their activation and is dependent on Ca2+ mobilisation (Wang et al.,
2002). To understand whether the mechanism of chRANKL expres-
sion was conserved between mammals and birds, chicken
splenocytes were stimulated with the intracellular calcium mod-
ulator, ionomycin, and the PKC activator, PMA, which mimic TCR
activation, for 2, 4 and 18 h and levels of chRANKL mRNA expres-
sion were analysed by qRT-PCR (Fig. 6A). In co-stimulated cells the
levels of chRANKL mRNA expression were signiﬁcantly increased
after 4 and 18 h indicating that ionomycin and PMAwork in synergy
to induce chRANKL mRNA expression. In murine T cells, ionomycin
alone was suﬃcient to induce RANKL expression and no synergy
was found when cells were co-stimulated with ionomycin and PMA
(Wang et al., 2002). In similar studies, murine T cell hybridomas
weakly induced RANKL after PMA stimulation but a combination
of PMA and ionomycin synergised and induced higher levels of
RANKL expression (Bishop et al., 2011; Fionda et al., 2007). The tran-
scriptional control of chRANKL and mammalian RANKL by Ca2+
modulation and PKC activation, as veriﬁed by inhibition studies
(Fig. 6B), is conserved between mammals and chickens.
The ability of schRANKL to induce or enhance pro-inﬂammatory
cytokine expression in immature or mature chicken APC was
analysed by qRT-PCR (Fig. 7). APCwere either unstimulated or stimu-
lated with LPS, schRANKL or both for 3 and 6 h. Costimulation of
BMDC with schRANKL and LPS led to a signiﬁcant increase in pro-
inﬂammatory cytokine mRNA expression levels compared to those
in unstimulated BMDC and, in some cases, LPS-stimulated BMDC.
SchRANKL-treatment alone did not signiﬁcantly alter pro-
inﬂammatory cytokines mRNA expression levels. BMM costimulated
with LPS and schRANKL signiﬁcantly increased IL-1β mRNA ex-
pression levels in comparison to unstimulated cells but not LPS-
stimulated cells. Pre-incubation with both schRANK-Fc and chOPG-
Fc decreased the schRANKL-mediated increase in pro-inﬂammatory
cytokine mRNA expression levels (Fig. 7). This also indicated that
the soluble receptors of chRANKL were capable of interacting with
their ligand.
SchRANKL treatment did not affect the expression levels of MHC
class II either alone or in combination with LPS (Fig. 8). CD40 ex-
pression levels were increased in LPS-stimulated cells but were not
enhanced by the addition of schRANKL. The expression pattern of
KUL01 was also analysed; although it is not an activation marker
like CD40 and MHC class II, KUL01 expression decreases as chicken
APC mature (Wu et al., 2010). This was therefore a good marker to
identify the ability of schRANKL to induce cell maturation. As ex-
pected, at 24 h LPS-treated cells had decreased KUL01 expression
but expression levels thereof were unaltered by schRANKL treat-
ment. Overall schRANKL does not mediate the upregulation of cell
surface activation markers in chicken BMDC, similarly to mamma-
lian RANKL (Anderson et al., 1997; Wong et al., 1997a).
Studies on the biological effect of mammalian RANKL on DC have
produced contrasting evidence as to its effect on their phenotype.
One of the ﬁrst studies examining the biological role of mamma-
lian RANKL proposed that RANKL-treated murine BMDC did not
signiﬁcantly increase expression levels of MHC class II, CD80 or CD86
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but did slightly (not signiﬁcantly) upregulate the expression of CD40
(Anderson et al., 1997; Wong et al., 1997a). Monocyte-derived DC
treated with RANKL increased surface expression of MHC class II,
CD80 and CD86 (Seshasayee et al., 2004), suggesting that DC derived
from different sources react differently to RANKL exposure. One study
(Park et al., 2005) on the bioactivity of mammalian RANKL on mac-
rophages suggested that RANKL-treated cells upregulatedMHC class
II expression which was enhanced when cells were co-stimulated
with LPS but not with IFN-γ. It is important to note that DC may
express RANK but react differently in their response to RANKL de-
pending on their tissue of origin. Our data indicate that chRANKL
has no effect on the phenotype of BMDC or BMM alone or in com-
bination with LPS (Fig. 8).
The lifespan of DC can inﬂuence the duration of lymphocyte
activation, thereby affecting the outcome of immune responses.Mam-
malian RANKL is a survival factor for DC andmacrophages (Anderson
et al., 1997; Cremer et al., 2002; Park et al., 2005;Wong et al., 1997a).
To determine the ability of schRANKL to enhance the survival rates
of BMDC and BMM, cells were untreated or treated with schRANKL
for 24 and 48 h (Fig. 9). BMDC survival rates were increased in
schRANKL-treated cells compared to untreated cells after 24 h and
48 h (Fig. 9). After 24 h, the number of viable cells was increased in
schRANKL-treated BMM compared to untreated cells. However, after
48 h schRANKL-treated cells had similar numbers of viable cells as
untreated cells. It seems that the ability of schRANKL to enhance the
survival of BMM is short-lived. Various mammalian studies have
shown that the upregulation of the Bcl-2 familymembers, Bcl-XL and
Bcl-2, are linked to RANKL-mediated cell survival (Izawa et al., 2007;
Josien et al., 1999;Wong et al., 1997a) and genetic andmolecular anal-
ysis fromnematodes to humans indicates that programmed cell death
is highly conserved (Ellis et al., 1991), so it is therefore plausible that
chRANKL may upregulate the levels of anti-apoptotic chicken Bcl-2
family members in BMDC and BMM.
5. Conclusion
In summary, chRANKL, chRANK and chOPGmRNA expression has
been analysed in different tissues and cells in the chicken. Expres-
sion of chRANKLmRNA and its receptors was detected across a wide
range of tissues. Both of the receptors for chRANKL are differen-
tially expressed in mature BMDC. The bioactivity of chRANKL has
been analysed in both BMDC and BMM indicating conservation of
RANKL bioactivities between mammalian and chicken in BMDC but
not completely in BMM.
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